Ypsomed Holding YPSN.SW
SwitzerlandHealthcare · Medical Instruments & SuppliesSIX Swiss Exchange · CHF
397.00 CHF (+9.3%)
13 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Ypsomed Holding is a Swiss company that designs, manufactures, and markets injection systems and drug delivery devices, such as insulin pens and pumps, for patients and the pharmaceutical industry.
Listed on SIX Swiss Exchange · Symbol YPSN.SW · SWX: YPSN · Currency CHF
Key points
from its scores- ✓Very solid balance sheet7.3
- ✓Favourable backdrop7.3
- ✕Demanding valuation3.6
- ✕Little or no dividend4.1
- !Moderate growth5.2
AI analysis
bottom line, main risk, context and newsBusiness quality is high, but valuation and cash generation do not justify an entry at the current time.
Ypsomed shows solid financial health (score 7.32) with low leverage (ND/EBITDA 0.71) and high profitability (ROE 31.09%), but its valuation is demanding (P/E 22.28) and free cash flow conversion is negative (-17.58%), which weighs on its attractiveness despite strong earnings growth (51.70%).
Negative free cash flow conversion (-17.58%) is the main risk, as it may limit investment capacity and shareholder returns despite high accounting profitability.
Context and risks
Ypsomed operates in the medical devices sector, a segment with stable demand and predictable regulation. No specific regulatory, geopolitical, or business model risks are identified that are not already reflected in its base risk profile. Exposure to interest rates is limited given its low leverage (Net Debt/EBITDA of 0.71).
Is Ypsomed Holding stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 22.3 | 26.7 | −17% |
| EV / EBITDA | 15.4 | 14.5 | +6% |
| Price / book | 6.4 | 4.1 | +55% |
| Price / sales | 6.5 | 3.4 | +91% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 397.00 CHF, +9.3% versus the price.
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 22.3
- Forward P/E
- 24.7
- EV / EBITDA
- 15.4
- Price / book
- 6.4
- Price / sales
- 6.5
- PEG
- 3.28
- Market cap
- 4.8B CHF
- Enterprise value
- 5.0B CHF
Profitability
- ROE
- 31.1%
- ROA
- 12.4%
- ROIC (approx.)
- 19.2%
- Gross margin
- 43.0%
- Operating margin
- 26.5%
- Net margin
- 30.4%
- Free cash flow
- −57.3M CHF
- FCF yield
- −1.2%
- Cash conversion
- −18%
Solvency
- Total debt
- 260.8M CHF
- Net debt
- 232.2M CHF
- Cash
- 28.6M CHF
- EBITDA
- 325.8M CHF
- Net debt / EBITDA
- 0.71
- Debt / equity
- 34.86
- Current ratio
- 1.07
- Quick ratio
- 0.73
Growth
- Revenue growth
- −13.3%
- Earnings growth
- +51.7%
- EPS (TTM)
- 16.30 CHF
- EPS (forward)
- 14.72 CHF
Dividend
- Dividend yield
- 1.2%
- Payout
- 13.5%
Risk and market
- Beta
- 0.81
- Analyst consensus
- Buy (13)
- Target price
- 397.00 CHF
- 52-week range
- 260.50 – 418.00
Recent news
All YPSN.SW news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Ypsomed Holding
Is Ypsomed Holding stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 3.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 397.00 CHF, +9.3% versus the price. This is not investment advice.
What score does Ypsomed Holding get on MeridIAn Screener?
It scores 5.7 out of 10, rank 1,295 of 2,130 (better than 39% of the companies analysed). Its strongest category is Financial health (7.3) and its weakest, Valuation (3.6). Analysis of 08/10/2026.
What is Ypsomed Holding's P/E ratio?
Its P/E is 22.3: the share price equals 22.3 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 24.7.
How much is Ypsomed Holding worth on the stock market?
Its market capitalisation is 4.8B CHF and its enterprise value, debt included, is 5.0B CHF.
How much debt does Ypsomed Holding have?
Its net debt (debt minus cash) is 232.2M CHF. That is 0.71 times its EBITDA; the Healthcare median is 1.53.
Does Ypsomed Holding pay a dividend?
Yes: its dividend yield is 1.21% and it pays out 14% of its earnings.
How has Ypsomed Holding stock performed over the last year?
It has risen 14.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 260.50 and 418.00 CHF. Past performance does not guarantee future results.
What do analysts think of Ypsomed Holding?
13 analysts cover it; their average recommendation is “Buy” and their average target is 397.00 CHF (+9.3% versus the price). It is an estimate, not market data.